The A4 Study: Stopping AD Before Symptoms Begin?-Reference-Cited by-同舟云学术

The A4 Study: Stopping AD Before Symptoms Begin?

Published:2014-03-19 Issue:228 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sperling Reisa A.¹²,Rentz Dorene M.¹²,Johnson Keith A.¹²³,Karlawish Jason⁴,Donohue Michael⁵,Salmon David P.⁵,Aisen Paul⁵

Affiliation:

1. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

2. Harvard Aging Brain Study, Department of Neurology and

3. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

4. Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA 19104, USA.

5. Alzheimer Disease Cooperative Study, University of California at San Diego, San Diego, CA 92093, USA.

Abstract

A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference10 articles.

1. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

2. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

3. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

4. Testing the Right Target and Right Drug at the Right Stage

5. Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment

Cited by 621 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explainable artificial intelligence identifies an AQP4 polymorphism-based risk score associated with brain amyloid burden;Neurobiology of Aging;2024-11

2. A Data-Driven Cognitive Composite Sensitive to Amyloid-β for Preclinical Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-09-06

3. The Alzheimer's Disease Neuroimaging Initiative Clinical Core;Alzheimer's & Dementia;2024-08-13

4. Parental History of Memory Impairment and β-Amyloid in Cognitively Unimpaired Older Adults;JAMA Neurology;2024-08-01

5. A survey study of Alzheimer’s stigma among Black adults: intersectionality of Black identity and biomarker diagnosis;Ethnicity & Health;2024-07-30